Evaluering af leveringen og virkningerne af THC-dampende væsker i blodbanen
Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Randomized Within-Subject Crossover Study
This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. Assess pharmacokinetic (PK)/pharmacodynamic (PD) profiles of THC vaping liquids administered with co-use of vaped nicotine.
II. Outcomes of interest will be assessed overall, and according to biological sex.
SECONDARY OBJECTIVES:
I. Safety. II. Assessment of differences in puffing behaviors. III. Short-term subjective drug effects, and cognitive performance following THC use without nicotine versus (vs.) THC use with pre-nicotine use vs. THC use with post-nicotine use in current consumers of both vaped cannabis and vaped nicotine products.
OUTLINE: Participants are randomized to 1 of 3 arms.
ARM A: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
- VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
- VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
ARM B: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
- VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
- VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
ARM C: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
- VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
- VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
All participants also undergo blood sample collection throughout the trial.
After completion of study intervention, participants are followed up at 30 days.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiesteder
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Kontakt:
- Danielle M. Smith
- Telefonnummer: 716-845-8403
- E-mail: Danielle.Smith@RoswellPark.org
-
Ledende efterforsker:
- Danielle M. Smith
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 21 years of age; (self-reported on screening, verified at study visit).
- Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).
- Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).
- Report use of THC vaping liquids at least weekly (4x/month); (self-reported).
- Daily use of nicotine vaping products containing >2% nicotine (>20mg/ml for at least 3 months prior to enrollment; (self-reported).
- Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures.
- Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.
- Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 1 day prior to each session.
- Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Exclusion Criteria:
-
Unwilling or unable to follow protocol abstinence requirements based on more than two instances of a positive THC saliva test (NarcoCheck Ref#:NCE-S THC-1).
-
Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted
-
Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported).
-
Report drinking alcohol more than 3x per week with 5 or more drinks per occasions (males) or with 4 or more drinks per occasion; (women).
-
Report of daily cigarette use; (self-reported).
-
Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).
-
Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported)
-
Current or prior diagnosis of chronic obstructive pulmonary disorder (COPD), cystic fibrosis, pulmonary hypertension, pulmonary edema, pulmonary embolus, or other uncontrolled respiratory conditions
-
Current cancer diagnosis.
-
Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).
-
Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).
-
Unwilling or unable to follow protocol requirements.
-
Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.
-
The following special populations will be excluded:
- Cognitively impaired adults/adults with impaired decision-making capacity
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
-
No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm A (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Andre navne:
Vape THC
Andre navne:
Vape active nicotine
Andre navne:
Vape placebo nicotine |
|
Eksperimentel: Arm B (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Andre navne:
Vape THC
Andre navne:
Vape active nicotine
Andre navne:
Vape placebo nicotine |
|
Eksperimentel: Arm C (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Andre navne:
Vape THC
Andre navne:
Vape active nicotine
Andre navne:
Vape placebo nicotine |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum concentration of THC in plasma (Cmax)
Tidsramme: Up to 21 days
|
Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries. |
Up to 21 days
|
|
Time to maximum concentration of THC in plasma (Tmax)
Tidsramme: Up to 21 days
|
Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models. |
Up to 21 days
|
|
Area under the plasma concentration-time curve from 0-120 minutes (AUC0-120)
Tidsramme: Up to 21 days
|
Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models |
Up to 21 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events (AEs)
Tidsramme: Up to 30 days after completion of study intervention
|
AEs will be summarized by nicotine condition and grade using frequencies and relative frequencies. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting. |
Up to 30 days after completion of study intervention
|
|
Puffing behaviors
Tidsramme: Up to 21 days
|
puff duration |
Up to 21 days
|
|
Puffing behaviors
Tidsramme: Up to 21 days
|
puff number |
Up to 21 days
|
|
Short-term drug effects
Tidsramme: Up to 21 days
|
The short-term drug effects (Drug Effects Questionnaire [DEQ), The DEQ rates sixteen component items using a visual analog scale (0-100) to examine drug effects pre- and post-use |
Up to 21 days
|
|
Marijuana Withdrawal Checklist [MWC)
Tidsramme: Up to 21 days
|
The Marijuana Withdrawal Questionnaire Total Score includes items assessing anxiety, depression, irritability, appetite, aggression/anger, sleep disturbance, somatic disturbances, and craving to use marijuana. The potential range of this total score is from "0" = no withdrawal symptoms to "47" = maximally high levels of withdrawal |
Up to 21 days
|
|
Digit Symbol Substitution Task (DSST)
Tidsramme: Up to 21 days
|
An assessment of cognitive dysfunction that test ability to complete daily tasks |
Up to 21 days
|
|
Paced Auditory Serial Addition Task (PASET)
Tidsramme: Up to 21 days
|
Measures of working memory and concentration . |
Up to 21 days
|
|
Tobacco Craving Questionnaire (Short Form)
Tidsramme: Up to 21 days
|
Self reported 47-item questionnaire that assesses tobacco craving. Items are rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree). Factor scores for each participant are obtained by summing the three items in each factor scale, yielding a score ranging from 3 to 21. |
Up to 21 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Danielle M Smith, Roswell Park Cancer Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Stof-relaterede lidelser
- Kemisk inducerede lidelser
- Misbrug af marihuana
- Pyridiner
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Alkaloider
- Solanaceous alkaloider
- Nikotin
- Håndtering af eksemplar
- Nabiximols
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- I-3597023
- R01DA057228 (U.S. NIH-bevilling/kontrakt)
- I-3597023 (Anden identifikator: Roswell Park Cancer Institute)
- NCI-2024-01556 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .